Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
-
Clinical Benefit
Substantial
The actual benefit of this proprietary drug is substantial.
Clinical Added Value
no clinical added value
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives.